DPD is enzyme in colorectal cancer tumor predicts response to Xeloda treatment. How to use precision medicine in colorectal cancer treatment selection? Patients with recurrent colon cancer had the same chance to respond to oxaliplatin and 5-Fluorouracil chemotherapy. Efficacy of capecitabine (Xeloda) in stage 3 colon cancer patients depends on DPD enzyme activity in colorectal cancer tumor. Therefore, DPD enzyme is a biomarker for selection of patients for whom Xeloda + oxaliplatin chemotherapy will work.
Home » Expert Centers » Colorectal Cancer » Capecitabine (Xeloda) therapy efficacy prediction. DPD enzyme gene expression in colon cancer. 5-2